Institutional members access full text with Ovid®

Share this article on:

Treatment Response in Pediatric Patients With Pseudotumor Cerebri Syndrome.

Tovia, Eliel MD; Reif, Shimon MD; Oren, Asaf MD; Mitelpunkt, Alexis MD; Fattal-Valevski, Aviva MD, MHA
Journal of Neuro-Ophthalmology: Post Author Corrections: August 04, 2017
doi: 10.1097/WNO.0000000000000516
Original Contribution: PDF Only

Background: Pseudotumor cerebri syndrome (PTCS) is a disorder defined by increased intracranial pressure in the absence of an intracranial space-occupying lesion. This retrospective study aimed to examine the outcomes in children with PTCS.

Methods: Data was collected retrospectively from the charts of consecutive pediatric patients treated for PTCS at our hospital between 2000 and 2007 (60 patients; 36 females, 24 males).

Results: Forty-six patients (76.6%) responded well to acetazolamide therapy, with full resolution of symptoms, including papilledema (average treatment duration 1 year; range: 1 month-5 years). Of the 14 patients with no response to treatment, 9 (23.4%) required surgical intervention. Nonresponders tended to be younger at presentation (8.7 vs 11.5 years, P = 0.04). Twelve patients (26%) experienced relapse after acetazolamide was discontinued. The group that experienced relapse was significantly younger than the nonrelapsers (8.9 vs 12.1 years, P < 0.05).

Conclusions: Younger age at presentation with PTCS was found to be a risk factor for treatment failure or relapse.

(C) 2017 by North American Neuro-Ophthalmology Society